HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J. — HUTCHMED (China) Limited today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). ELUNATE® is a selective oral inhibitor of...
Latest News
This is the second indication for Hiyasta® in Japan following adult T-cell leukemia/lymphoma (A TLL) SAN DIEGO – HUYABIO International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R)...
HyVIS, the European project coordinated by the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), is about to start. By combining nanotechnology and optics, it will develop bionic synapses for retinal prostheses, designed to restore sight in people suffering from diseases such as retinitis pigmentosa and age-related macular degeneration (AMD)....
BUDAPEST, Hungary – HYD LLC has done pioneering work in the field of research on deuterium depletion and of developments based on that, its innovative activity laid the fundaments of a novel pharma and food industry. Hungarian molecular biologist, Gábor Somlyai PhD, in the early ‘90s foremost started to investigate...
INDIANAPOLIS — Clinical research led by Indiana University School of Medicine investigators and their collaborators in Uganda has revealed that hydroxyurea significantly reduces infections in children with sickle cell anemia. Their latest findings enhance strong evidence of hydroxyurea’s effectiveness and could ultimately reduce death in children in Africa, the continent...
Hyper-cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus rituximab (hyper-CVAD-R) can prevent central nervous system (CNS) relapse in patients with Burkitt leukemia/lymphoma (BL) or high-grade B-cell lymphoma (HGBL), according to a study published in Blood Advances. The retrospective study included 79 patients with newly diagnosed BL (n=54) or HGBL (n=25) who were treated...
NEW YORK — In recent decades, there have been periodic reports of a worldwide decline in sperm count and quality. Male infertility has ostensibly been on the rise, accompanied by increases in testicular cancer and hypospadias — a congenital defect in which the opening of the urethra is on the...
SHANGHAI and GAITHERSBURG, Md. – I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in an abbreviated combination clinical study (NCT04202003) of lemzoparlimab (also known as TJC4) with azacitidine (AZA) in patients with newly...
GENOA, Italy — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that the first subject was treated with IAMA-6, an orally administered small molecule therapeutic targeting NKCC1. IAMA-6, IAMA’s lead program, is being evaluated for...
SHANGHAI and NANJING, China and SAN JOSE, Calif., — IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for Equecabtagene Autoleucel (IASO Bio R&D...